Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.
about
Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies.The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophyA comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscleA human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophyHigh throughput screening for compounds that alter muscle cell glycosylation identifies new role for N-glycans in regulating sarcolemmal protein abundance and laminin bindingSarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration.Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophyDeletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient miceComparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junctionN-Glycolylneuraminic acid deficiency worsens cardiac and skeletal muscle pathophysiology in α-sarcoglycan-deficient miceOverexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type miceOverexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient miceThe synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.Congenital muscular dystrophy. Part II: a review of pathogenesis and therapeutic perspectives.Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates.Cell-matrix interactions in muscle disease.Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.Distinct contributions of Galgt1 and Galgt2 to carbohydrate expression and function at the mouse neuromuscular junction.O-fucosylation of muscle agrin determines its ability to cluster acetylcholine receptors.Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy.Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.Lectin-binding characterizes the healthy human skeletal muscle glycophenotype and identifies disease-specific changes in dystrophic muscle.
P2860
Q22001192-37BB3AB7-676F-414A-822C-BDC7917D222BQ26827638-4A7F429E-10CA-4BE6-AA5B-F7C708C162A8Q27322890-484D8463-26E0-4331-A901-DEC4D0C059D4Q34175938-8B3C52B5-F5BC-4579-BBE8-4DBB55C30B34Q34262912-DDAD5AF4-EE4E-43A8-B31A-183847C14DB6Q34284175-0F0EB2FC-40B8-44F4-8ADE-D7ED2CCEC9A4Q35952091-8F38FEA6-1BDC-4E85-8BA1-6D4D4B45C772Q36167600-2A2018EC-9F29-4243-83A8-7EDF52438299Q36218358-ABAB7166-E7A0-4449-99FC-7229E75EFE18Q36321503-D66544CE-F760-499F-B6B9-C3F6DDDD0C62Q36900455-349081F8-D939-4B6D-922B-DCBBF2517145Q37139061-53117913-EC12-43D4-977D-A9CEDEFD9DFAQ37257159-7D112F85-EF8B-4EFD-94FB-C98754E21181Q37361308-BF0CB8FD-978D-449F-8906-9845475F3FD0Q37528083-73798BBB-162D-437D-AFB0-C7EAE8DEC24FQ37696027-4DA22F64-9487-488C-8ED9-2A269ACB1858Q37944530-883FCE1A-F2AB-44B4-91CF-6A142964B82CQ38874623-C4CD3B75-90BC-4B79-B79B-25DABC973C75Q39044467-D9A45A14-04FC-4AFE-94FC-40D4CFF7D60DQ39453819-F708E42E-A297-4F95-B4BB-46CC8F73F5DDQ41267697-B5CB32B3-1B61-407F-B9EC-073D45DBDB76Q41854050-7F316096-6CED-4C63-95BD-5C9FCC59D822Q41881081-D6D16596-5090-4A07-85F9-52AC4E0C3F51Q42489627-F806CA98-DF21-4F3B-9BA4-05EDD516E40AQ42947899-44D0ACCD-C39B-40E7-A77E-F04D2C455DD9Q43980966-76D523CA-3847-4166-B592-A12069900E1E
P2860
Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Overexpression of the cytotoxi ...... genital muscular dystrophy 1A.
@ast
Overexpression of the cytotoxi ...... genital muscular dystrophy 1A.
@en
type
label
Overexpression of the cytotoxi ...... genital muscular dystrophy 1A.
@ast
Overexpression of the cytotoxi ...... genital muscular dystrophy 1A.
@en
prefLabel
Overexpression of the cytotoxi ...... genital muscular dystrophy 1A.
@ast
Overexpression of the cytotoxi ...... genital muscular dystrophy 1A.
@en
P2093
P2860
P921
P1476
Overexpression of the cytotoxi ...... genital muscular dystrophy 1A.
@en
P2093
Jung Hae Yoon
Kumaran Chandrasekharan
Marybeth Camboni
Paul T Martin
P2860
P304
P356
10.2353/AJPATH.2007.060927
P407
P577
2007-07-01T00:00:00Z